The highest dose of AstraZeneca’s small molecule halved levels of a type of “bad” cholesterol after 12 weeks, hitting the ...

Corcept Therapeutics’ oral antiglucocorticoid plus chemotherapy slashed risk of ovarian cancer progression by 30% compared to ...

AI drug discovery firm Isomorphic Labs has completed the company’s first external funding round since its 2021 founding ...

GE HealthCare has raised the curtain on a new CT system with features designed specifically for addressing cardiovascular ...

Apollomics has sold the rights to its lead c-MET inhibitor in Asia, excluding Greater China, to Taiwan’s LaunXP Biomedical ...

Opthea’s eye disease drug has failed its second phase 3 trial in a week, leaving the Australian biotech to discard the entire ...

BiomX’s acquisition of Adaptive Phage Therapeutics is looking like a good bet now that one of the treatments from the deal ...

Transcend also saw significant improvements on secondary endpoints that assessed the rate of response, remission and loss of ...

Cologuard is getting an upgrade after 10 years on the market, as Exact Sciences starts to roll out the new version of its ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...

Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, bolstering the company’s argument that the siRNA candidate has an edge over ...